Press Release Archives
CRISPR Therapeutics AG
CRISPR Therapeutics AG develops gene-based medicines for patients with serious diseases. Its therapeutic molecular level using the breakthrough genome-editing technology called CRISPR-Cas9. The company was founded by Rodger Novak, Emmanuelle Charpentier and Shaun Patrick Foy in 2014 and is headquartered in Basel, Switzerland.

CRISPR Therapeutics AG Press Releases

Press Archives

CRISPR Therapeutics AG

Press Archives

CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference

May 7th 2020

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results

Apr 28th 2020

CRISPR Therapeutics Proposes Changes to the Board of Directors

Feb 26th 2020

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results

Feb 12th 2020

CRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference

Jan 6th 2020

CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies

Nov 19th 2019

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results

Oct 28th 2019

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

May 1st 2019

May 1, 2019 ZUG, Switzerland and CAMBRIDGE, Mass., May 01, 2019 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating tr

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results

Apr 29th 2019

April 29, 2019 -Enrollment ongoing in Phase 1/2 clinical trials of CTX001™ for patients with severe hemoglobinopathies- -IND and CTA approved for CT

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia

Apr 16th 2019

April 16, 2019 ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, April 16, 2019 -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorpor

CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2019 Annual Meeting

Feb 27th 2019

February 27, 2019 ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 27, 2019 -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on crea

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

Feb 25th 2019

February 25, 2019 -First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia- -First patient enrolled in a Phase